Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection

Liver International

Volumn 25, Issue 3, 2005, Pages 571-579

  Zhang, Hai Ying ^a   Nanji, Amin A ^a,b   Luk, John M ^a   Huang, Xiao Ru ^a,c   Lo, Chung Mau ^a   Chen, Yong Xiong ^a   Yuen, Siu Tsan ^a   Lan, Hui Y ^a,c   Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

HBV; Hepatic injury; Inflammation; MIF

Indexed keywords

ALANINE AMINOTRANSFERASE; CD45RO ANTIGEN; CYTOKINE; HEPATITIS B SURFACE ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CELL INFILTRATION; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LIVER CELL; LIVER INJURY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; FEMALE; GENE EXPRESSION; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; LIVER; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MALE; MIDDLE AGED; NECROSIS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 20844446169     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01047.x     Document Type: Article

References (52)

1. Malik A H, Lee W M. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132: 723-31.
2. Lau G K K. Hepatitis B infection in China. In: Holland K K, ed. Clinics in Liver Disease 2001; 5:361-79.
3. Chisari F V, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
4. Chu C M. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastrol Hepatol 2000; 15(Suppl.): E25-30.
5. Yang H I, Lu S N, Liaw Y F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
6. Lin S M, Sheen I S, Chien R N, Chu C M, Liaw Y F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
7. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
8. Lau D T, Everhart J. Kleiner D E, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-7.
9. Chisari F V, Klopchin K, Moriyama T, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-56.
10. Roger T, David J, Glauser M P, Calandra T. MIF regulates innate immune responses through modulation of toll-like receptor 4. Nature 2001; 414: 920-4.
11. Calandra T, Spiegel L A, Metz C N, Bucala R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 1998; 95: 11383-8.
12. Bacher M, Meinhardt A, Lan H Y, et al. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 1997; 150: 235-46.
13. Nishino T, Bernhagen J, Shiiki H, Calandra T, Dohi K, Bucala R. Localization of macrophage migration inhibitory factor (MIF) to secretory granules within the corticotrophic and thyrotrophic cells of the pituitary gland. Mol Med 1995; 1: 781-8.
14. Calandra T, Bernhagen J, Mitchell R A, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994; 179: 1895-902.
15. Bacher M, Meinhardt A, Lan H Y, et al. MIF expression in the rat brain: implications for neuronal function. Mol Med 1998; 4: 217-30.
16. Wada S, Fujimoto S, Mizue Y, Nishihira J. Macrophage migration inhibitory factor in the human ovary: presence in the follicular fluids and production by granulosa cells. Biochem Mol Biol Int 1997; 41: 805-14.
17. Rossi AG, Haslett C, Hirani N, et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998; 101: 2869-74.
18. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine 1998; 10: 199-205.
19. Meyer-Siegler K, Fattor R A, Hudson P B. Expression of macrophage migration inhibitory factor in the human prostate. Diagn Mol Pathol 1998; 7: 44-50.
20. Baugh J A, Donnelly S C. Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. Endocrinology 2003; 179: 15-23.
21. Calandra T, Spiegel L A, Metz C N, Bucala R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA 1998; 95: 11383-8.
22. Hudson J D, Shoaibi M A, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppresser activity. J Exp Med 1999; 190: 1375-82.
23. Kamimura A, Kamachi M, Nishihara J, et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer 2000; 89: 334-41.
24. Repp A C, Mayhew E S, Apte S, Niederkorn J Y. Human uveal melanoma cells produce macrophage migration-inhibitory factors to prevent lysis by NK cells. J Immunol 2000; 165: 710-5.
25. Meyer-Siegler K. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Interferon Cytokine Res 2000; 20: 769-78.
26. Bini L, Mgi B, Marzocchi B, et al. Protein expression profiles in human breast ductal carcinoma and histology of normal tissue. Electrophoresis 1997; 18: 2832-941.
27. Akbar S M, Abe M, Murakami H, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett 2001; 171: 125-32.
28. Lau G K, Tsiang M, Hou J, et al. Combination therapy with lamivudine and fameiclovir for chronic hepatitis B infected Chinese: a viral dynamics study. Hepatology 2000; 32: 394-9.
29. Lau G K, Leung Y H, Fong D Y, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324-30.
30. Lo J W, Leung A Y, Huang X R, et al. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients. Bone Marrow Transplant 2002; 30: 375-80.
31. Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
32. Wu P C, Fang W S, Lai C L, et al. Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. Am J Clin Pathol 1996; 105: 87-95.
33. Lan H Y, Mu W, Yang N, et al. De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 1996; 149: 1119-27.
34. Lan H Y, Yang N, Nikolic-Paterson D J, et al. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000; 57: 499-509.
35. Donnelly S C, Haslett C, Reid P T, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3: 320-3.
36. Makita H, Nishimura M, Miyamoto K, et al. Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med 1998; 158: 573-9.
37. Mikulowska A, Metz C N, Bucala R, Holmdahl R Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type ii-induced arthritis in mice. J Immunol 1997; 158: 5514-7.
38. Leech M, Metz C, Hall P, et al. Macrophage migration inhibitory factor in rheumatoid arthritis - evidence of proinflammatory function and regulation by glucocorticoids Arthritis Rheum 1999; 42: 1601-8.
39. Bacher M, Metz C N, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 7849-54.
40. Satoskar A R, Bozza M, Rodriguez Sosa M, Lin G, David J R. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun 2001; 69: 906-11.
41. Calandra T, Echtenacher B, Le Roy D, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor (MIF). Nat Med 2000; 6: 164-9.
42. Benigni F, Atsumi T, Calandra T, et al. The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000; 106: 1291-300.
43. Bacher M, Metz C N, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 7849-54.
44. Abe R, Peng T, Sailors J, Bucala R, Metz C N. Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 2001; 166: 747-53.
45. Bernhagen J, Calandra T, Mitchell R A. Purification and characterization of the cytokine macrophage-migration inhibitory factor (MIF). FASEB J 1994; 8: A1417.
46. Onodera S, Suzuki K, Matsuno T, Kaneda K, Takagi M, Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology 1997; 92: 131-7.
47. Mitchell R A, Metz C N, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 1999; 274: 18100-6.
48. Nakamoto Y, Guidotti L G, Kuhlen C V, Fowler P, Chisari F V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341-50.
49. Lau G K, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002; 122: 614-24.
50. Gray D. Immunological memory. Annu Rev Immunol 1993; 11: 49-77.
51. Leech M, Metz C N, Santos L. et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 1998; 41: 910-7.
52. Ogawa H, Nishihira J, Sato Y, et al. An antibody for macrophage, migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. Cytokine 2000; 12: 309-14.